StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Wednesday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD opened at $1.11 on Wednesday. TherapeuticsMD has a 52 week low of $0.70 and a 52 week high of $2.75. The stock’s 50-day moving average price is $1.29 and its 200-day moving average price is $1.56.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP boosted its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. Institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.